Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Drouet, Valérie ^a,b   Ruiz, Marta ^a,b   Zala, Diana ^b,c,d   Feyeux, Maxime ^e   Auregan, Gwennaëlle ^a,b   Cambon, Karine ^a,b   Troquier, Laetitia ^f   Carpentier, Johann ^a,b   Aubert, Sophie ^e   Merienne, Nicolas ^f   Bourgois Rocha, Fany ^e   Hassig, Raymonde ^a,b   Rey, Maria ^f   Dufour, Noëlle ^a,b   Saudou, Frédéric ^b,c,d   Perrier, Anselme L ^e   Hantraye, Philippe ^a,b   Déglon, Nicole ^a,b,f  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b CNRS   (France)

^c INSTITUT CURIE   (France)

^d INSERM   (France)

^e I Stem   (France)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HUNTINGTIN; MESSENGER RNA; SHORT HAIRPIN RNA; HTT PROTEIN, HUMAN; MUTANT PROTEIN; NERVE PROTEIN; RNA ISOFORM; SMALL INTERFERING RNA;

ADULT; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; EMBRYONIC STEM CELL; GENE; GENE MUTATION; GENE SILENCING; GENE TARGETING; HTT GENE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRUS INFECTION; MALE; MICROTUBULE; NEURAL STEM CELL; NEUROPATHOLOGY; NONHUMAN; PROTEIN TRANSPORT; RAT; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL CULTURE; CYTOLOGY; DISEASE MODEL; GENE THERAPY; GENETICS; HEK293 CELL LINE; HUNTINGTON DISEASE; METABOLISM; MOUSE; PROCEDURES; RNA STABILITY; WISTAR RAT;

ANIMALS; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; GENETIC THERAPY; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; IN VITRO TECHNIQUES; MALE; MICE; MUTANT PROTEINS; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RATS, WISTAR; RNA ISOFORMS; RNA STABILITY; RNA, SMALL INTERFERING;

EID: 84903156434     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099341     Document Type: Article

References (49)

1. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, et al. (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577. (Pubitemid 16196286)
2. The, Huntington's disease collaborative research (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 72: 971-983.
3. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993. (Pubitemid 27449140)
4. Zhang Y, Friedlander RM (2011) Using non-coding small RNAs to develop therapies for Huntington's disease. Gene Ther 18: 1139-1149.
5. Drouet V, Perrin V, Hassig R, Dufour N, Auregan G, et al. (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65: 276-285.
6. Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, et al. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053-1063.
7. Hu J, Liu J, Corey DR (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 17: 1183-1188.
8. Fiszer A, Mykowska A, Krzyzosiak WJ (2011) Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res 39: 5578-5585.
9. Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, et al. (2012) Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression. Cell 150: 895-908.
10. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, et al. (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 100: 7195-7200. (Pubitemid 36706415)
11. Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, et al. (2008) Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 3: e3341.
12. Ostergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41: 9634-9650.
13. Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, et al. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19: 774-778.
14. Lombardi MS, Jaspers L, Spronkmans C, Gellera C, Taroni F, et al. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 217: 312-319.
15. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, et al. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 19: 2178-2185.
16. Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, et al. (2009) CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84: 351-366.
17. Warby SC, Visscher H, Collins JA, Doty CN, Carter C, et al. (2011) HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 19: 561-566.
18. Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, et al. (2012) Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet 90: 434-444.
19. Menalled LB (2005) Knock-in mouse models of Huntington's disease. NeuroRx 2: 465-470.
20. Bowles KR, Brooks SP, Dunnett SB, Jones L (2012) Gene expression and behaviour in mouse models of HD. Brain Res Bull 88: 276-284.
21. Lundberg C, Bjorklund T, Carlsson T, Jakobsson J, Hantraye P, et al. (2008) Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 8: 461-473.
22. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555-1567. (Pubitemid 36857303)
23. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6182-6195.
24. Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, et al. (2013) A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet 22: 18-34.
25. Hottinger AF, Azzouz M, Deglon N, Aebischer P, Zurn AD (2000) Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 20: 5587-5593. (Pubitemid 30636884)
26. Feyeux M, Bourgois-Rocha F, Redfern A, Giles P, Lefort N, et al. (2012) Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells. Hum Mol Genet 21: 3883-3895.
27. Mateizel I, De Temmerman N, Ullmann U, Cauffman G, Sermon K, et al. (2006) Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders. Hum Reprod 21: 503-511. (Pubitemid 43159929)
28. Bradley CK, Scott HA, Chami O, Peura TT, Dumevska B, et al. (2011) Derivation of Huntington's disease-affected human embryonic stem cell lines. Stem Cells Dev 20: 495-502.
29. Tropel P, Tournois J, Come J, Varela C, Moutou C, et al. (2010) High-efficiency derivation of human embryonic stem cell lines following pre-implantation genetic diagnosis. In vitro cellular & developmental biology Animal 46: 376-385.
30. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118: 127-138. (Pubitemid 38902819)
31. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498. (Pubitemid 32494397)
32. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031-1044.
33. van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, et al. (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 19: 710-719.
34. de Almeida LP, Ross CA, Zala D, Aebischer P, Deglon N (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 22: 3473-3483. (Pubitemid 37465753)
35. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267. (Pubitemid 26119138)
36. Deglon N, Tseng JL, Bensadoun JC, Zurn AD, Arsenijevic Y, et al. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther 11: 179-190. (Pubitemid 30044050)
37. Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 21: 2219-2232.
38. Zala D, Colin E, Rangone H, Liot G, Humbert S, et al. (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17: 3837-3846. (Pubitemid 352762847)
39. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al. (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637. (Pubitemid 36638089)
40. Wei N, Zhang L, Huang H, Chen Y, Zheng J, et al. (2012) siRNA has greatly elevated mismatch tolerance at 3'-UTR sites. PLoS ONE 7: e49309.
41. Wu L, Fan J, Belasco JG (2008) Importance of translation and nonnucleolytic ago proteins for on-target RNA interference. Current biology: CB 18: 1327-1332.
42. Davidson BL, McCray PB Jr. (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340.
43. Davidson BL, Monteys AM (2012) Singles engage the RNA interference pathway. Cell 150: 873-875.
44. Bowers WJ, Breakefield XO, Sena-Esteves M (2011) Genetic therapy for the nervous system. Hum Mol Genet 20: R28-41.
45. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, et al. (2007) Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 18: 195-206. (Pubitemid 46626459)
46. Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, et al. (2006) Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 13: 463-483. (Pubitemid 43257615)
47. Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355.
48. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
49. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, et al. (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383: 1138-46.